Trametinib: Phase III started

GlaxoSmithKline began the double-blind, placebo-controlled, international Phase III COMBI-AD trial to evaluate twice-daily 150 mg oral dabrafenib ( GSK2118436) plus once-daily 2 mg

Read the full 237 word article

User Sign In